ArticleOncoTargets and therapy2018
Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Melatonin in cancer treatment.The Cochrane database of systematic reviews · 2025Pooled it
- Evaluation of the Individual Effects of Melatonin and Umbilical Cord-Derived Mesenchymal Stem Cell Exosomes on Cell Viability and Apoptosis in BE(2)-C Neuroblastoma Cells In Vitro.Current issues in molecular biology · 2026Article
- Melatonin in Integrative Oncology: Biological Mechanisms, Therapeutic Evidence and Implementation Strategies.Oncology research · 2026Review
- Circadian Rhythm Disruption in Cancer Survivors: From Oncogenesis to Quality of Life.Cancer medicine · 2024Review
- The Potential of Integrative Cancer Treatment Using Melatonin and the Challenge of Heterogeneity in Population-Based Studies: A Case Report of Colon Cancer and a Literature Review.Current oncology (Toronto, Ont.) · 2024Review
- Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival.Current oncology reports · 2024Review
- Effects of Antioxidant Dietary Supplement Use upon Response to Cancer Treatment: A Scoping Review of Available Evidence.Nutrition and cancer · 2024Article
- The Effects of a Combination of Medical Cannabis, Melatonin, and Oxygen-Ozone Therapy on Glioblastoma Multiforme: A Case Report.Reports (MDPI) · 2023Article
- Radiation-induced liver disease: beyond DNA damage.Cell cycle (Georgetown, Tex.) · 2023Review
- Melatonin Inhibits EMT in Bladder Cancer by Targeting Autophagy.Molecules (Basel, Switzerland) · 2022Article
- The Effect of Melatonin Intake on Survival of Patients with Breast Cancer-A Population-Based Registry Study.Cancers · 2022Article
- Melatonin as the Cornerstone of Neuroimmunoendocrinology.International journal of molecular sciences · 2022Review
- Melatonin Protects Chronic Kidney Disease Mesenchymal Stem/Stromal Cells against Accumulation of Methylglyoxal via Modulation of Hexokinase-2 Expression.Biomolecules & therapeutics · 2022Article
- Lung Pneumonitis and Fibrosis in Cancer Therapy: A Review on Cellular and Molecular Mechanisms.Current drug targets · 2022Review
- Protective role of melatonin in breast cancer: what we can learn from women with blindness.Cancer causes & control : CCC · 2022Review
- Melatonin MTAmerican journal of physiology. Lung cellular and molecular physiology · 2021Article
- The Interplay between Housing Environmental Attributes and Design Exposures and Psychoneuroimmunology Profile-An Exploratory Review and Analysis Paper in the Cancer Survivors' Mental Health Morbidity Context.International journal of environmental research and public health · 2021Review
- Exploring the link between chronobiology and drug delivery: effects on cancer therapy.Journal of molecular medicine (Berlin, Germany) · 2021Review
- Review
- Melatonin upregulates DNA-PKcs to suppress apoptosis of human umbilical vein endothelial cells via inhibiting miR-101 under HMolecular and cellular biochemistry · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMelatonin (MLT), a kind of neuroendocrine active substance, has been reported to function in the treatment of tumors. However, there remain controversies about the curative effect of MLT in tumors in clinical studies. This study investigates the efficacy of MLT on tumor therapeutic strategies by meta-analysis.
methodsAfter searching several main literature databases, a total of 5,057 articles were obtained and screened by inclusion and exclusion criteria. The tumor remission rate, overall survival rate, and incidence of side effects were recorded and analyzed in the included study patients. Group analysis and sensitivity analysis were performed to examine the sources of heterogeneity in the pooled studies.
resultsThe tumor remission rate in the MLT group was significantly higher than that in the control group (relative risk [RR] =2.25; 95% CI, 1.86-2.71;
conclusionMLT exerts positive influence in tumor therapeutic strategies, including improving tumor remission rate and overall survival rate, while reducing the incidence of chemotherapy side effects. Further large-scale randomized clinical trials (RCTs) are urgently required to verify therapeutic effects of MLT in tumors by various clinical research centers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.